Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Ineffective erythropoiesis in MDS

Moshe Mittelman • 5 Mar 2020
MDS 2020
Anemias Myelodysplastic Syndromes Luspatercept

Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, discusses the research into ineffective erythropoiesis in myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Moshe Mittelman

4:16
Pre-MDS states: identifying patients at risk and using modern tools to improve prognosis
Moshe Mittelman • 5 May 2023
3:39
The role of inflammation in MDS & the potential to target it to prevent and treat MDS
Moshe Mittelman • 5 May 2023
3:37
Lymphoid aggregates as a potential prognostic factor for MDS
Moshe Mittelman • 5 May 2023
1:41
Using cytogenetics to improve the diagnosis and prognosis of MDS & to predict response to treatment
Moshe Mittelman • 5 May 2023

Related Videos

1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals